Jacqueline M. Kraveka

Hematology | Oncology
171 Ashley Ave
Charleston, SC 29425

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Bridging the Gap in Neuroblastoma Care: Consensus-Based Statements With Recommendations for Improved Patient and Caregiver Experiences.

Bridging the Gap in Neuroblastoma Care: Consensus-Based Statements With Recommendations for Improved Patient and Caregiver Experiences.

Journal: Pediatric blood & cancer
Published: April 06, 2026

Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.

Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.

Journal: Research square
Published: April 08, 2024

Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.

Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma.

Journal: Leukemia
Published: March 21, 2024

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 26, 2023

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.

Journal: Genome medicine
Published: August 17, 2023

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.

Journal: International journal of cancer
Published: December 16, 2022

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 13, 2022

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

Journal: Cancer reports (Hoboken, N.J.)
Published: September 10, 2021

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.

Journal: Cancer research
Published: April 02, 2021

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.

Journal: International journal of cancer
Published: March 04, 2020

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

Journal: JAMA
Published: August 28, 2019

Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.

Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.

Journal: Bioorganic & medicinal chemistry
Published: August 14, 2018
Showing 1-12 of 26

Last Updated: 09/26/2026